Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab plus chemotherapy as bridging therapy before CD19 CAR-T in relapsed/refractory DLBCL
KCT0011523Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Started Jul 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0011523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011523.